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PENILAIAN EKONOMI DAN FAKTOR MEMPENGARUHI  
BERHENTI ROKOK MENGGUNAKAN PROGRAM iSTOP  




Produk tembakau umpama serampang dua mata. Produk tembakau bukan 
sahaja menyumbang kepada ekonomi negara malah, ia juga merupakan faktor risiko 
kepada kesihatan manusia dan pencuri senyap kekayaan penggunanya, masyarakat dan 
negara. Selain daripada kos penjagaan kesihatan, prestasi kerja perokok turut terjejas 
mengakibatkan penurunan produktiviti. Banyak kajian menunjukkan bahawa program 
berhenti merokok di tempat kerja adalah berkesan dan menjana simpanan positif 
kepada majikan. Oleh itu, pemberhentian merokok di tempat kerja dilihat sebagai satu 
strategi yang berpotensi untuk memerangi penggunaan produk tembakau. Banyak 
kajian telah dijalankan di luar negara tetapi kajian tempatan adalah kurang, 
terutamanya dalam sektor pembuatan swasta. Ini adalah satu kajian kohort prospektif 
keratan rentas tunggal pemberhentian merokok di tempat kerja yang dijalankan di 
sebuah syarikat pembuatan tempatan. Kajian ini mengkaji program intervensi berhenti 
merokok yang inovatif dengan multi-komponen selama 12 minggu untuk menyokong 
pekerja yang merokok berhenti merokok. Program ini dikenali sebagai program 
“iSTOP”. Objektif kajian adalah untuk menilai keberkesanan program inovatif ini dan 
tingkah laku perokok serta mengenal pasti faktor yang mempengaruhi berhenti 
merokok dan kembali merokok. Di samping itu, kualiti program ini juga dinilai dengan 
mengunakan kaedah analisis kualitatif, menjadikannya lebih berkesan dalam 
membantu perokok berhenti merokok. Oleh kerana program ini ditaja sepenuhnya oleh 
Syarikat, bahagian terakhir adalah mengira pulangan ekonomi kepada majikan dengan 
xxi 
menggunakan penunjuk komersil biasa (ROI dan IRR) yang biasa digunakan oleh 
pihak Pengurusan. Kajian ini juga merupakan kajian pertama yang memberi ubat 
Varenicline dan kombinasi Varenicline dengan terapi gentian nikotin (NRT) di tempat 
kerja. Hasil kajian ini amat menggalakkan. Sejumlah 155 orang perserta mengambil 
bahagian dan mereka dibahagikan kepada dua kumpulan untuk mengikuti program 
iSTOP. Secara keseluruhan kadar berhenti merokok untuk jangka pendek dan jangka 
panjang masing-masing 45.8% dan 37.4%. Analysis multivariate menyimpulkan 
bahawa faktor-faktor yang mempengaruhi perberhentian merokok jangka panjang 
selama satu tahun adalah tahap kepatuhan kepada program intervensi klinikal dan 
mempunyai persepsi yang kuat terhadap kesan merokok ke atas kesihatan. Faktor-
faktor yang berkaitan dengan mereka kembali merokok adalah tinggal di kawasan 
bandar, percubaan berhenti merokok kurang daripada 1 minggu dan tidak menerima 
nasihat GP pada tahun semasa. Semua peserta yang ditemuramah menghargai usaha 
yang dilakukan oleh Syarikat untuk menganjur program ini secara percuma. 
Penggunaan varenicline dan gabungannya dengan NRT telah diterima baik oleh 
peserta.  Kesanggupan diri, efikasi kendiri dan motivasi diri dengan sokongan dan 
motivasi yang berterusan dari persekitaran adalah faktor kritikal kejayaan berhenti 
merokok. Ini membawa kepada penciptaan model “CARE” untuk program 
pemberhentian merokok di tempat kerja. ROI dalam 5 tahun dan IRR setahun program 
in masing-masing 156% and 20.7%, mengesahkan bahawa program “iSTOP” adalah 
satu projek pelaburan yang menarik bagi pihak Pengurusan.  Kesimpulannya, tesis ini 
menesahkan bahawa program pemberhentian merokok di tempat kerja berkesan dan 
memberi manfaat kepada majikan. Tindakan masa depan termasuklah memasukkan 
model “CARE” dalam program berhenti merokok di tempat kerja supaya 
keberkesanan program dapat ditingkatkan lagi. 
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ECONOMIC EVALUATION AND FACTORS AFFECTING 
SMOKING CESSATION USING iSTOP PROGRAM 
IN A LOCAL MANUFACTURING COMPANY  
ABSTRACT 
Tobacco products are a double-edged sword. While tobacco products 
contribute to a country’s economic significantly, it is also a notable risk factor for 
human health and a silent thief of the wealth of its users, society and nation. Apart 
from the healthcare cost, the work performance of smokers is also being affected 
leading to lower productivity. Many studies have also shown that workplace smoking 
cessation programs are effective and have generated positive savings for the employers. 
Therefore, workplace smoking cessation has been viewed as a potential strategy to 
combat the usage of tobacco products. Abundant studies have been carried out abroad, 
but local studies are scares; especially in the private manufacturing sector. This study 
was a cross-sectional single prospective cohort workplace smoking cessation study 
conducted in a local manufacturing company. This study reviewed a 12-week 
innovative multi-component smoking cessation intervention program to support 
smoking employees to quit smoking, called “iSTOP” program. The objectives of this 
study were to evaluate the effectiveness of this innovative program and the smokers’ 
behaviours as well as to identify factors affecting smoking cessation and relapse. On 
top of these, the quality of this program was also evaluated using qualitative analysis 
method, making it more effective in assisting smokers to quit smoking. As this was the 
Company fully sponsored program, the last section was to calculate the economic 
return this program to the employer using the common commercial indicators (ROI 
and IRR), which are familiar by the Management team. This study was also the first 
xxiii 
study prescribing varenicline and the combination of varenicline with nicotine 
replacement therapy (NRT) in a workplace setting. The results of this study were very 
encouraging. A total of 155 participants took part, and they were divided into two 
batches to go through the iSTOP program. The overall short-term and long-term 
abstinent rates were 45.8% and 37.4% respectively. The multivariate analysis 
concluded that the factors affecting abstinence for one year were the level of adherence 
to the clinical intervention program and having a strong perception of the effect of 
smoking on health. Factors related to relapse were staying in the urban area, previous 
quit attempt of less than 1 week and not receiving GP’s advice in the current year. All 
the interviewed participants valued the effort put on by the Company for this free-of-
charge program. Use of varenicline and its combination with NRT were well-accepted 
by the participants. Self-willingness, self-efficacy and self-motivation with continuous 
support and motivation from the surroundings were critical factors in successful 
smoking cessation. This lead to the development of “CARE” model for workplace 
smoking cessation program. The ROI over 5 years and IRR per year of this program 
were 156% and 20.7% respectively, confirming that iSTOP program was a promising 
investment project for the Management. In conclusion, this thesis confirmed that 
iSTOP program was effective and benefited the employers. Future actions were to 
apply the “CARE” model in a workplace smoking cessation program to further 
enhance its effectiveness.
1 





Cigarette is a highly engineered, pleasure, addictive and deadly tobacco product. It 
contains nicotine and releases more than 7,000 toxic chemical compounds when 
burning (U.S. Department of Health and Human Services, 2014). Nicotine is an 
addictive active pharmaceutical compound. It contains in cigarette, which the only 
legal drug that delivers nicotine to the brain immediately after inhaling, as effective as 
intravenous injection, but is not regulated as controlled medicine  (World Health 
Organization, 2008, 2015). 
Smoking gives “carrots and sticks” to smokers. In the early group of smoking, its users 
gain sensory gratification (calming, relaxation, reward, alertness and confidence), 
social crutch and weight lost. Over the time, smokers not only develop addiction and 
dependence on nicotine but also habit. Unfortunately, apart from the dependence, 
smoking is a gradual killer. Tobacco contained in the cigarettes kills half of its users 
when it is used as per the manufacturers instruction and on average 15 years 
prematurely (Institute for Public Health (IPH), 2012; World Health Organization, 2008, 
2015) It effects nearly all organs of the body will be seen only after a lag of several 
years, which ultimately, threaten the health and reducing the wealth of the smokers 
(U.S. Department of Health and Human Services, 2014; World Health Organization, 
2008). 
Since the landmark 1964 Surgeon General’s report published, the evidence on smoking 
and health has expanded greatly (U.S. Department of Health and Human Services, 
2014). Nowadays, tobacco smoking including second-hand smoke is known to be the 
leading preventable causes of premature morbidity and mortality in the world today 
(U.S. Department of Health and Human Services, 2014; World Health Organization, 
2011). Tobacco kills a third to half of its users 15 years prematurely and one person is 
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killed every 6 seconds (U.S. Department of Health and Human Services, 2014)  If 
current trend continues, tobacco will kill one person every 4 seconds and up to 1 billion 
of smokers could be killed in 21st century (World Health Organization, 2012). More 
importantly, the premature death of smokers raises the cost of healthcare, deprives 
household income of smoking families and hinders economic development of a 
country (Institute for Public Health (IPH), 2012).  
Unfortunately, the impact of smoking has been screened by smokers and hence only 
the pleasure of smoking is acknowledged. Currently, there are about 1.3 billion 
smokers globally and is expected to increase to 1.6 billion by 2025 (Clive & Andy, 
2004; Elgoni, 2010). Developing countries comprise 73% of the world smoker’s 
population (Elgoni, 2010; H. K. Lim et al., 2013; Peto, 1994). 
In 2015, Malaysia has about 5 million smokers, comprising 22.8% of the Malaysian 
population aged 15 years and above. 43.0% of Malaysia men smoke while only 1.4% 
of women smoke. Prevalence of smoking in the rural areas (24.3%) was slightly higher 
than the urban areas (22.7%). About 60% of them smoke 15 or more cigarettes per day 
with average daily consumption 12 cigarettes per day (Institute for Public Health (IPH), 
2015a; Wee, Shahab, Bulgiba, & West, 2011). 
In Malaysia, at least 15% of the total hospitalisations are due to smoking (K. H. Lim 
et al., 2009; Yong et al., 2013). Smoking-related diseases have been the primary cause 
of mortality since 1980 (H. K. Lim et al., 2013). It is estimated that annually 10,000 
deaths and 35% of hospital deaths are attributed to smoking (K. H. Lim et al., 2009; 
Yong et al., 2013). A study on the burden of disease estimated that one-fifth of 
disability adjusted life years (DALYs) and one-third of years of life lost (YLL) for 
Malaysians were due to smoking-related diseases (Institute for Public Health (IPH), 
2015a; H. K. Lim et al., 2013). 2.92 billion Ringgit Malaysia was spent on treating 
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three major smoking-related diseases, namely lung cancer, ischemic heart disease and 
chronic obstructive pulmonary disease (COPD) (Al-Naggar, Jawad, & Bobryshev, 
2012; Cheah & Naidu, 2012; H. K. Lim et al., 2013). If the current trend continues, it 
is estimated that by 2020, 30,000 smokers will die due to smoking-related diseases 
yearly (K. H. Lim et al., 2009). In order to achieve the World Health Organisation Non 
Communicable Diseases Global target, there is a need to reduce current smoking 
prevalence to 15% by the year 2025 (Institute for Public Health (IPH), 2015b). 
Many activities have been carried out by the Malaysia Government to reduce the 
smoking prevalence. “Tak Nak Merokok” (Don’t want Smoking) was launched in 
2004 to increase the public awareness on the harmfulness of smoking to the smokers 
and second-hand smoke. In Jan 2007, “Infoline” for smoking cessation was established 
to help smokers and family of a smoker to quit smoking (Kassim & Mohd Zain, 2015). 
To promote smoking cessation, Melaka became first state in the country to gazette five 
areas as no-smoking zones in 2011(Murali, 2011). This was followed by Penang, 
which announced the heritage enclave and Penang Hill to be smoke-free area in 2016 
and 2017 respectively (Arnold, 2016; Edmund, 2017). Meanwhile, Penang aimed to 
be smoke-free state by 2023 (The Star/Asia News Network, 2018). KUALA Lumpur 
City Hall (DBKL) aimed to be fully smoke-free city in the future to reduce the 
prevalence of smoking in the city (The Star, 2018). 
About 70% of Malaysian adult smokers are working, spending minimally 9 hours in 
their working places.  As the nicotine withdrawal symptoms usually start within a few 
hours after the last cigarette, these smokers need to smoke during working hours. 
Approximately 40% of those who work indoors had been exposed to second-hand 
smoke in their workplace (Institute for Public Health (IPH), 2015b). There are enough 
evidences showing that smoking has harmful effects to health not only to smokers but 
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also second-hand smokers (Mattias Öberg, 2010). Therefore, smoking in the 
workplace has detrimental effect not only on the employees’ health, but also imperil 
the safety and healthy as well as productivity of the workplace (Institute for Public 
Health (IPH), 2012; Robert C. Klesges, Cigrang, & Glasgow, 1987; S. P. Tsai, Wen, 
Hu, Cheng, & Huang, 2005).  
Smoking is a remarkably refractory and sticky behaviour. Therefore, quitting smoking 
is not easy. In fact, very few tobacco users can successfully quit the habit easily. 
Therefore, many studies have been conducted to understand the factors affecting 
successful smoking cessation. Many predictors have been identified as predictors for 
smoking cessation; including older age, being male, married, having higher education, 
higher social economic status, no smoking or smoking partner at home, has been 
smoking for more than 15 years, low addiction to nicotine, previous quit attempts, 
smoke-free policy at workplace, self-motivated and self-confidence (Biener, Hamilton, 
Siegel, & Sullivan, 2010; Bravin et al., 2015; Caponnetto & Polosa, 2008; Ezat, 
Selahuddeen, & Aljunid, 2008; Fai, Yen, & Malik, 2016; Ghani et al., 2012; Kim, 
2014; Lee & Kahende, 2007; Li et al., 2010). In general, these factors are found in the 
both abroad and local studies.  
Smoking is such an irresistible and inviting behaviour or habit. Those smokers who 
have stopped smoking easily lapse and hence relapse. About 65& to 75% of the ex-
smokers would relapse from abstinent in the first year (Lee & Kahende, 2007). 
Therefore, studies have also been conducted abroad and local to understand the 
predictors for relapse from smoking cessation. Some factors related to relapse are 
younger age, high level of nicotine dependence, experiencing nicotine withdrawal 
symptoms, smoking environment in both home and workplace, depression, poor social 
support in workplace and prior quit attempt that last for less than six months (Batra, 
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Collins, Torchalla, Schroter, & Buchkremer, 2008; Buczkowski, Marcinowicz, 
Czachowski, & Piszczek, 2014; Caponnetto & Polosa, 2008; Li et al., 2010; Wee et 
al., 2011).  
Therefore, the essential in quitting journey is to address both addictive and behavioural 
aspects. There are two types of smoking cessation interventions: behavioural and 
pharmacological, which could be administered as monotherapy or in combination. 
These different smoking cessation interventions have been studied extensively in many 
controlled or uncontrolled studies and reviewed by many researchers and positioned 
in smoking cessation guidelines (Anderson & Wetter, 1997; Ebbert, Elrashidi, & Stead, 
2015; Glynn, Cryan, Kent, Flynn, & Kennedy, 2009; Dorothy K. Hatsukami & 
Mooney, 1999; J. Hughes, 2008; Jiloha, 2014; Lancaster, Stead, Silagy, & Sowden, 
2000; Schmelzle, Rosser, & Birtwhistle, 2008). Apart from these two mainstay 
treatments, other quitting methods are also available, including hypnotherapy, 
acupuncture, electronic cigarettes, and aversion therapy (Maseeh & Kwatra, 2005; 
Niaura et al., 2008; White, Rampes, Liu, Stead, & Campbell, 2014).  
There are nine validated pharmacotherapy, four validated behavioural interventions 
for smoking cessation (J. Hughes, 2008). The pharmacotherapy is divided into first-
line medications, consisting of all 5 types of nicotine replacement therapy formulations 
(gum, lozenges, patch, inhaler, and nasal spray), bupropion and varenicline. The 
second-line medications are Clonidine and Nortriptyline. The behavioural 
interventions are psychosocial treatment, which could be divided into first line, which 
consists of Group discussion, individual discussion and telephone help line. The 
second line behavioural interventions are rapid smoking and internet program. All 
these intervention have been validated and proven to be effective in assisting smokers 
during their quitting process and listed in the algorithm for choosing among smoking 
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cessation treatments (J. Hughes, 2008). These interventions also have been reviewed 
to be effective with sufficient evidences in Malaysia Clinical Practice Guideline of 
Tobacco Use and Disorder 2016 (Disease Control Division, 2016; J. Hughes, 2008).  
Quitting smoking is difficult because it is a cluster of behavioural, cognitive and 
physiological phenomena (Piasecki, 2006). Therefore, pharmaco-behavioural therapy, 
which is the combination of Pharmacotherapy and behavioural intervention, is 
developed (J. Hughes, 2008). Review study concluded that combined 
pharmacotherapy and non-pharmacotherapy increased quitting rate 82% compared to 
usual non-pharmacotherapy cessation method (Patnode et al., 2015). Hence smoking 
cessation support is crucial to help the smokers to quit successfully (Glynn et al., 2009).  
With the anti-smoking campaigns and restricting or banning tobacco advertisement, 
awareness on the harmfulness of smoking has been increased making many smokers 
want to quit smoking. However, only a few get the support they need. Currently, in 
Malaysia smoking cessation service is available as health services in selected 
government hospitals and government clinics. The smokers have to make an effort to 
visit the smoking cessation clinics which operate during working hours only. Therefore, 
workplace becomes an ideal setting for implementing smoking cessation intervention 
to support smoking working adults to quit smoking.  
The smoking cessation program implemented in the workplace were varied 
significantly, from a simple and low-intensity program; such as telephone counselling 
or self-help program to a comprehensive and high-intensity multicomponent program, 
such as self-help manuals, group counselling, mass media campaign, and smoking 
policy (Cahill & Lancaster, 2014). Therefore, the outcome of the studies on the 
effectives of a workplace smoking cessation program varies.  
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Workplace smoking cessation program is very feasible as majority of the smokers are 
adults. In Malaysia, about 70% of them were working (Institute for Public Health 
(IPH), 2012, 2015b). About half of the current smokers made a quit attempt in the past 
12 months. Therefore, implementing smoking cessation intervention at workplace 
would provide much support to smokers who intend to quit smoking but they could 
not visit the smoking cessation clinic due to their job responsibilities.  
Therefore, smoking cessation program will be a main source of information and 
support for the smoking employees to assist them to quit smoking effectively. It gives 
them convenience, particularity if the program is held during working hours and at the 
workplace. The program will also help them to reduce their expense in quitting 
smoking and increase their savings if their employers subsidize all or part of the 
program fee. They will not only regain their health but also their wealth. Initially, the 
smokers will spend to purchase tobacco products and enjoy the pleasure from smoking. 
Later years, they will have to spend purchase tobacco products to maintain their 
addiction and also spend to treat illnesses related to smoking, such as respiratory 
diseases, cardiovascular diseases, cancer and other disease.  
The losses and expenditure which the employers suffer from their smoking employees 
are significant. They have not only increased healthcare cost but also productivity lost, 
due to poor health, absenteeism, presenteeism, accidents and injuries (Berman, Crane, 
Seiber, & Munur, 2014; Halpern, Dirani, & Schmier, 2007b; Halpern, Shikiar, Rentz, 
& Khan, 2001; Robbins et al., 2000; Sindelar, Duchovny, Falba, & Busch, 2005; Weng, 
Ali, & Leonardi-Bee, 2013). In US, the healthcare cost of smokers was about 35% per 
year higher than non-smokers (Berman et al., 2014). The smokers were also 35%-43% 
more being absence than never smoking employees (Sindelar et al., 2005). In UK, 
smoking employees were absent at an average of 2.74 more days per year or 19% 
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increased risk of absenteeism compared with abstainers (Weng et al., 2013).  
Therefore, workplace smoking cessation program indeed, over a long-term period of 
4 years, will reduce the healthcare cost and increase their smoking employees’ 
productivity as well as reduce absenteeism (Cahill & Lancaster, 2014; Javitz et al., 
2004; Javitz, Zbikowski, Swan, & Jack, 2006; Robert C. Klesges et al., 1987). It will 
eventually generated benefit-cost ration of 8.75 (Warner, Smith, Smith, & Fries, 1996). 
The workplace smoking cessation program has many advantages.  It has access to 
many smokers who would make a relatively stable population for the quit smoking 
program. This population is unique to the community or clinical setting as they know 
each other and hence will encourage sustained per-group support among them. 
Moreover, they could also get support from their non-smoking colleagues. Some may 
feel positive peer pressure too if their peers have stopped smoking successfully.  
Another significant benefit is that the participants do not need to travel if the program 
is held at the workplace during office hours. It also gives an opportunity to target the 
young population which are relatively healthy and do not seek doctors’ consultations 
frequently. Moreover, the company occupational health staffs could be hand on to give 
professional support. Therefore, workplace smoking cessation program has a higher 
participation rate, which leads to higher smoking cessation rates compared with non-
workplace environment(Cahill & Lancaster, 2014). 
1.2 Problem statement 
Workplace smoking cessation program have been evaluated and reviewed since 1970s 
(Cahill & Lancaster, 2014; Danaher, 1980; Robert C. Klesges et al., 1987). Many 
studies evaluating efficacy of workplace smoking cessation programs and have 
unanimously concluded that workplace is an appropriate and convenient setting for 
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implementing smoking cessation program due to its stable smoking population and 
ease of access to the smoking cessation program (Danaher, 1980; Robert C. Klesges 
et al., 1987; Smedslund, Fisher, Boles, & Lichtenstein, 2004; Stachnik & Stoffelmayr, 
1983). 
Systemic review on these intervention studies have reported diverged outcomes and 
the overall evaluation of its effectiveness is held back by a large heterogeneity in 
intervention. A meta-analysis conducted in 1990 on the long-term (average=l2  months) 
abstinence  rates  of  smoking  cessation  programs  held  in  the workplace  in  North  
America  concluded that one  year  quit rates ranged from  3%  to  28%,  with  13%  as  
a  reasonable benchmark  for  assessing  the  effectiveness  of future  smoking cessation  
efforts (K. J. Fisher, Glasgow, & Terborg, 1990). About 10 years later, another meta-
analysis on newer studies revealed that the quit rates were higher with 1 year quit rate 
of 20.8%; but the effect seemed to diminish over time and was not present beyond 12 
months (Smedslund et al., 2004).  
All the available studies explored effectiveness of the workplace smoking cessation 
program were conducted abroad; except a study conducted by Noor et al 2011, which 
evaluated efficacy of an herbal compound (Viva QS®) (Noor, Aris, Mohamed, Draman, 
& Bux, 2011).  Other local studies were conducted among students and staffs of local 
universities (Yasin, Retneswari, Moy, Taib, & Ismail, 2013). 
All the workplace smoking cessation studies by different researches have been using 
different interventions in their program. Therefore, till to-date, there is no standard 
approach being recommended for workplace smoking cessation program. Moreover, 
the lack of local workplace smoking cessation studies using different interventions in 
the manufacturing industry has also caused the local employers not convincing of the 
feasibility of implementing workplace smoking cessation program in the workplaces. 
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There have been many studies reviewing the factors affecting smoking cessation and 
relapse from smoking. Some studies had different findings. For example, female in 
Korean was concluded to be more likely to quit smoking than males (Kim, 2014). At 
the same time, some workplace studies had different findings from other community 
studies, which being married did not associated with smoking cessation (Yasin et al., 
2013). In Malaysia, studies reviewing these factors were mainly based on population 
from smoking cessation clinics and university. There has been no study to review these 
factors based on the population from manufacturing industry. 
Generally, interventions which are effective in non-workplace settings are effective in 
workplace settings. A recent 2014 review showed strong evidences that group therapy, 
individual counselling, pharmacotherapies and multi-components smoking cessation 
intervention program increased cessation rate in comparison to no treatment or 
minimal intervention controls. (Cahill & Lancaster, 2014) Most of the workplace 
smoking studies applied these interventions studied in non-workplace settings in 
workplace settings using similar implementation strategies and standardized 
intervention components. For example, workplace smoking cessation studies involved 
pharmacological therapy applying a standard nicotine replacement therapy (NRT) 
regimen to the all participants (Cahill & Lancaster, 2014; Smedslund et al., 2004). 
Study evaluating effectiveness of flexible and individualized treatment program is 
lacking (Aubin, Karila, & Reynaud, 2011; Bell, McCullough, et al., 2007b). 
Varenicline tartrate, a partial cholinergic nicotinic agonist, assisting the smokers to 
manage their addiction to nicotine and nicotine withdrawal symptoms during quitting 
is the latest anti-smoking medicine introduced to the market since 2006 (Antonopoulos 
& Bercume, 2007; Ebbert, Hays, & Hurt, 2010). It appears to generate highest long-
term quit rates. Large clinical trials have also demonstrated the superiority of 
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varenicline over bupropion SR and NRT for increasing quit rate among cigarette 
smokers (Aubin, 2009; Cahill, Stead, & Lancaster, 2012; Ebbert et al., 2010). Despite 
its high initial cost, it is recommended as the first-line option and also has been proven 
to be cost-effective for smoking cessation (Faulkner, 2009; Garrison & Dugan, 2009). 
However, post-marketing surveillance and case reports related Varenicline with high 
incidence of nausea occurring in 16% to 42% of varenicline-treated subjects and 
potential neuropsychiatric adverse effects events, such as depressed mood, agitation, 
and suicidal ideation (Oncken et al., 2006). This creates worries among the practitioner 
while prescribing it to working adults and hence till to-date, it has not been studied in 
any of the workplace smoking cessation study (McClure et al., 2009). 
Smoking has been seen as individual habit where smokers have to make their own 
effort and be responsible to correct it. Therefore, worrying increased cost of 
administration and reported low quit rate, Malaysia’s employers generally have low 
interest in conducting the workplace smoking cessation program. Moreover, anti-
smoking medicine is not covered by the insurance companies. Even if the employers 
would like to support, internal and external resources to implement the workplace 
smoking cessation program are also lacking and local guidance is not available. 
Studies conducted to evaluate the benefits of workplace smoking cessation using 
financial indicator, such as ROI (return on investment) and IRR (internal rate of return) 
are limited and only available in the abroad studies. These studies were mainly related 
to the pharmacotherapy (Javitz et al., 2004; Javitz et al., 2011). Only one study has 
been known to calculate the economic return from the employers perspective using 
ROI (Mulligan, 2010). It was estimated that the ROI of workplace smoking cessation 
ranged from minimal of 300% to a maximum of 1400% (Mulligan, 2010).   
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1.3 Rational of study 
In Malaysia, community smoking cessation programs have been available from quit 
smoking clinic for more than 2 decades in Malaysia (NoorZurani & Mohammad 
Hussain, 2012). The quit rates reported were 17.3% and 31.8% respectively (Ezat et 
al., 2008; Wee et al., 2011). The pharmacist-led integrated quit smoking program 
achieved higher quit rate of 42.6% (Fai et al., 2016). Unfortunately, its reach to the 
smokers is very limited because it is not known widely by smokers and the service is 
only available during working hours. Hence, workplace smoking cessation program 
becomes plausible to support smoking employees to stop smoking so as to curb the 
increasing trend of smoking.  
The currently available studies evaluating the effectiveness of the workplace smoking 
cessation programs using different interventions were mainly studied abroad, such as 
United States, United, Austria, Finland, Japan and other countries. Due to the 
differences in social and culture, there is a need to evaluate applicability and 
effectiveness of these interventions locally and the acceptance of the smoking workers.  
Meanwhile, most of these interventions were carried out in the general community 
without leveraging the unique characteristic of a workplace. Moreover, no study is 
evaluating the use of Varenicline in the workplace. The local research on the factors 
affecting smoking cessation and relapse among the workers from the manufacturing 
industry is scared as well. 
Workplace smoking cessation program is new to Malaysia. Only limited resources and 
knowledge are available to support companies to provide workplace smoking cessation 
program to the smoking employees. Limited studies have been conducted in local 
workplace environment, which reported quit rate of 30.7% in a manufacturing 
company and 13% in local university (Noor et al., 2011; Yasin et al., 2013). 
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 Meanwhile, evidences are available showing that workplace smoking cessation 
programs are not only benefit smoking employees but also have direct benefits to the 
employers. It can yield positive cost savings for employers by increasing productivity 
and reducing the risk of fire hazards due to cigarette butts. Ultimately, a company’s 
image is improved (Halpern et al., 2007b; Halpern et al., 2001; Lundborg, 2007). 
Unfortunately, majority of the employers in Malaysia view that smokers would not 
stop smoking successful after attending the smoking cessation program and for those 
who had stop smoking, they will relapse after a period. Moreover, they viewed that the 
smoking cessation success rate is low and the running cost is high, especially when 
pharmacotherapy is provided, which is not covered by the local insurance companies. 
Therefore, many companies are reluctant to implement workplace smoking cessation 
programs.  
There are many studies concluded workplace smoking cessation program did bring 
positive economic impact to the employers (Ekpu & Brown, 2015; Halpern et al., 
2007b; Halpern et al., 2001; Igarashi et al., 2016; Parrott & Godfrey, 2004). Hence, 
this study is timely in encouraging other local employers to consider implementing 
smoking cessation program in their workplaces. The outcome of this study could be 
the beginning for future study or reference for developing guidance for any local 
company which intend to implement workplace smoking cessation program. The 
findings of the economic return could also be shared with the local employers to 
convince them the benefits of the workplace smoking cessation program and to 




1.4 Study objectives 
 
Based on the previous workplace smoking cessation studies in other countries program, 
a local multi-component workplace smoking cessation program was planned to be 
conducted in a large manufacturing company. This study focused on workplace 
smoking cessation program. It evaluated the effectiveness of an innovative workplace 
multi-component smoking cessation intervention program in reducing smoking 
prevalence in a large manufacturing company as well as the cost and benefits of this 
workplace smoking cessation program. 






1.5 Significance of study 
Findings from this study will benefits to various stakeholders; including smokers, 
smoking cessation providers, employer, researchers, and the Country. 
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For smokers, especially those working in the studied company, they will experience a 
guided, structure, systematic and medicated quitting process; instead of quitting 
themselves without any support. Those who have stopped successfully will then 
sharing their experiences with other smokers who are motivated to quit smoking. They 
also could be the ambassador for quitting smoking to encourage smokers who are in 
the pre-contemplating and contemplating stages to quit smoking.  
Due to difference of culture and healthcare system between foreign countries and 
Malaysia, smoking cessation programs studied in other countries may not be suitable 
in the local context. Hence, findings from this study will help the smoking cessation 
providers to structure a more effective workplace smoking cessation program for local 
companies. Researcher will also have this initial data to plan for the future study.  
Having positive findings will encourage the employer to continue implementing this 
workplace smoking cessation program for the smokers. Moreover, these local positive 
findings will also encourage other employers to conduct workplace smoking cessation 
program for their smoking employees to reduce smoking prevalence in their 
companies. 
It is hoped that the findings from this study will help the Ministry of Health to develop 
a guideline on the smoking control in the workplace and how the employer could 
implement smoking cessation program in their workplace. 
1.6 Thesis overview 
This research was conducted in all major cities of Malaysia. It utilised both quantitative 
and qualitative research techniques. This thesis reported the outcome of the objectives 
discussed in Chapter 1 as shown in Table 1.1. 
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Table 1.1: Thesis outline 
Chapter Objectives 
Chapter 2 Review literatures about methods in quitting smoking, especially used in 
workplace, efficacy of workplace smoking cessation program, verification of 
the outcome of smoking cessation program, factors affecting smoking cessation 
and relapse as well as general profiles of smokers in Malaysia  
Chapter 3 Described the qualitative and quantitative methodologies which are relevant 
to the research work of this thesis. 
Chapter 4 Understand social-demographic and smoking behaviours of the participants in 
this study 
Chapter 5 Evaluate short-term efficacy of iSTOP program by assessing 7-day point 
prevalence abstinence 
Chapter 6 Evaluate long-term efficacy of iSTOP program by assessing 52 weeks 
continuous abstinence  
Chapter 7 Quantitative evaluation on the variables affecting smoking cessation and 
relapse  
Chapter 8 Perform qualitative assessment on the effectiveness of iSTOP program and 
insights of success in quitting smoking 
Chapter 9 Perform economic analysis of iSTOP program 
Chapter 10 Thesis conclusion. Recommendation for workplace smoking cessation studies 





 LITERATURE REVIEW 
 





2.1 Literature review 
2.1.1 Background 
Tobacco use is a social malady. Decades of scientific research have concluded that 
tobacco use is the leading cause of premature morbidity and mortality in the world 
(U.S. Department of Health and Human Services, 2014). Nevertheless, use of tobacco 
has never been stopped, discontinued or even regulated. If the trend of tobacco 
consumption continues, billions of people worldwide will be killed by tobacco over 
the 21st century (Warner & Mackay, 2008). In response to globalisation of tobacco 
epidemic, WHO developed Framework Convention on Tobacco Control (FCTC) and 
entered into force in 2005 with the objective to protect present and future generations 
from the devastating health, social, environmental and economic consequence of 
tobacco consumption as well as exposure to tobacco smoke. It sets out the minimum 
actions that government must take pertaining to tobacco related matters; including 
provisions for supply and demand reduction as well as protection of environment. 
(Warner & Mackay, 2008). 
Apart from the public-health approaches, medical interventions in smoking cessation 
is also important. Medical intervention, both behavioural and pharmacological and 
therapy are effective evidence-based methods to improve health and also being proven 
as the most cost-effective remedies in medicine (Cromwell, Bartosch, Fiore, 
Hasselblad, & Baker, 1997; D. K. Hatsukami, Stead, & Gupta, 2008). Therefore, 
review will be begun by evaluating all the available smoking cessation interventions 
methods followed by methods of validating smoking status of the abstainers. 
Validating smoking status is a crucial step to assure the quality of a study as it affects 
the outcome of the study (Jarvis, Tunstall-Pedoe, Feyerabend, Vesey, & Saloojee, 
1987; SRNT Subcommittee on Biochemical Verification, 2002).  
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Apart from clinic-based intervention, a subset is application of the smoking cessation 
interventions in workplace settings; which has also been researched considerably since 
1960s. It is noted that generally smoking interventions applied in non-workplace 
settings were studied in workplace settings. Workplace is a rather stable and small 
community. Therefore, review will be focused on smoking cessation programs held in 
workplaces. It evaluates the current literatures that evaluates effectiveness of 
workplace smoking cessation programs and its economic impacts to employers. Hence, 
review on the available literatures will present an overview of this topic and helps in 
planning for further research to fill the gaps identified from the current literatures. 
Smoking is a pleasure and sticky behaviour (Piasecki, 2006).  Therefore, relapse is 
common and quitting smoking successfully in first quit attempt is rare. In general, 
smokers will make a 7 - 8 attempts before quitting smoking successfully (Disease 
Control Division, 2016). Hence, it is crucial to understand smoking behaviour and 
factors affecting quitting attempt taken by the smokers. Considering work environment 
and the triggering factors among working adults, will further enhance the quality of 
the workplace smoking cessation program. 
2.1.2 Search Strategy 
Published literatures were identified by a systemic search strategy via computer. 
Search was focus on English literatures and was performed from databases available 
at the university library; including Medline, Pubmed, Ebsco host, Science Direct, 
Wiley Interscience, Cochrane Database of Systematic Reviews, Springerlink, 
Blackwell Synergy, Sage, Ovid, and Scopus as well as internet search engine such as 
google and google scholar.   
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A series of keywords were used to identify the topic of interest using text word search 
for all fields; such as ‘smoking’, ‘smoking cessation’, ‘quit smoking’, ‘stop smoking’, 
‘smoking factor’, ‘smokers’, ‘workplace’, ‘worksite’, ‘intervention’, ‘cigarette’, 
‘tobacco’, ‘nicotine’, ‘nicotine dependence’, ‘addiction’, ‘health impact’, ‘economic 
evaluation’. Some of these keywords were used in combination. On top of the database 
search, the literature search was also supplemented by examining the reference list of 
literatures identified. Eligibility of the literatures for this review were published studies, 
published workplace smoking cessation guidelines or review articles or report 
prepared by trustworthy organization, such as Ministry of Health of Malaysia, World 
Health Organisation (WHO) National Institute for Health and Care Excellence (NICE), 
U.S. Department of Health and Human Services, quit smoking organization and peer-
reviewed articles. These literatures were written in English. Due to available of the 
vast literatures, aligned with the topic of discussion in this study, the search focused 
on the healthy population only. Thereafter, a database of references was compiled. 
2.1.3 Interventions for Smoking Cessation  
Since the release of the first report of the Surgeon General's Advisory Committee on 
Smoking and Health, the smoking society has evolved towards quit smoking milieu 
and the number of people giving up smoking has increased yearly. New quitting 
smoking method and programs have also been developed and studied to help the 
smokers to quit effectively. 
Nicotine contained in the cigarettes, has made its users addicted to smoking and crave 
for cigarette if smoking is discontinued. This smoking behaviour repeats consistently 
over a period, at last making smoking becomes a habit. This explains the difficulty in 
quitting smoking whereby nearly half of the smokers who have stopped smoking 
without any support, could only stop for less than a week and less than 5% remain 
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abstinent for a year (Hughes, Keely, & Naud, 2004; McRobbie, Bullen, Hartmann-
Boyce, & Hajek, 2014). There are two approaches in quitting smoking, “cold turkey” 
and “cutting down”. “Cold turkey” is the most common used approach. Please refer to 
Appendix A for details of these two approaches. 
Therefore, during the quitting journey, it is crucial to support the quitters 
physiologically to overcome the nicotine withdrawal symptoms and psychologically 
to overcome their smoking habit as well as enhance their motivation to quit (Aubin et 
al., 2011).  Study had shown that support given during smoking cessation will generate 
quit rate up to 20% (Zhu, Melcer, Sun, Rosbrook, & Pierce, 2000). 
2.1.3(a) Behavioural intervention 
Behavioural intervention is a non-pharmacological approach and is also known as 
advice, coaching, counselling, psychotherapy or psychosocial treatments (J. Hughes, 
2008). It improves smoking cessation outcomes via three components of therapies: 
behavioural (change habit to anticipate and avoid smoking cues), motivation (list down 
the reasons of why not smoking) and cognitive (learn to reduce and cope with nicotine 
withdrawal symptoms as well as urge to smoke). It could be delivered in different 
format by a trained counsellor, via telephone, face-to-face (individual and groups) or 
by a medium, via printed materials, video, televisions or internet (self-help programs).  
The content could be standard or tailored to individual at various frequency and 
duration. Moreover, these interventions could be implemented alone or in combination; 
such as group therapy plus telephone counselling. It could also be delivered in clinical 
setting or broad dissemination to a geographic community or workplaces. Appendix B 
described these interventions in detail. 
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Overall, all these interventions were effective compared to no intervention. How this 
intervention is delivered to the quitters affects the intensity and efficacy of the 
treatment, from minimal intervention to intensive intervention with different content 
and frequency; determined by the content, frequency and its medium. Meanwhile, 
there is a strong relationship between intensity and the efficacy of the treatment. The 
intervention duration and number of sessions also will affect the quit rates. For 
example, counselling could be delivered minimally which is normally 3 minutes of 
less (“minimal contact”) or delivered briefly between 3 and 10 minutes (“brief 
counselling”) or counselled for more than 10 minutes (“counselling”).  The quit rate 
for these 3 types of counselling were 11%, 12% and 19% respectively, compared to 
no counselling of 9% (Anderson & Wetter, 1997). It is noted that the longer is the 
intervention duration, the higher is the efficacy. Intervention duration of 2 weeks, 2-4 
weeks, 4-8 weeks, longer than 8 weeks recorded quit rates of 10%, 16%, 16% and 24% 
respectively (Anderson & Wetter, 1997).  
Meanwhile, it is also noted that increasing the number of contact will increase the quit 
rate due to due to additional contact and assessments (Anderson & Wetter, 1997; 
Hartmann-Boyce, Lancaster, & Stead, 2014; Lancaster et al., 2000). Nevertheless, the 
optimal number of session is between four and seven for counselling. Increasing the 
number of treatment session to more than seven had shown no significant increase in 
the quit rate (Anderson & Wetter, 1997; Dorothy K. Hatsukami & Mooney, 1999). 
It is also noted that those interventions having tailored content to the quitters and more 
interactive are more effective that standard content and not interactive. This was seen 
in tailored self-help, telephone calls and internet-based intervention. For internet-based 
and telephone interventions, it was noticed that effectiveness was increased when it 
was interactive (Gilbert, Nazareth, Sutton, Morris, & Godfrey, 2008; Hartmann-Boyce 
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et al., 2014; Stead, Hartmann-Boyce, Perera, & Lancaster, 2013). Nevertheless, self-
help materials targeted solely to group characteristics (for example age, gender, or race) 
were no superior than standard materials (Lancaster et al., 2000).  
The content of the counselling will also increase the quit rates. The content could be 
general problem-solving skills, such as recognition of danger situations which may 
increase the likelihood of smoking, coping skills under danger situations (example 
stress, drinking alcohol) and information about smoking and quitting. Clinical support 
during counselling, such as encourage the smokers to make quit attempt as well as care 
and concern about the smokers well-being during quitting will also affect the success 
of quit attempts (Anderson & Wetter, 1997; Dorothy K. Hatsukami & Mooney, 1999).  
Having the flexibility of tailoring messages and interactive sessions with the quitters 
as well as the number of counselling sessions, explains that of all the behavioural 
intervention, individual counselling and group counselling are most effective (Miller 
& Wood, 2003). This, of course, had to be delivered by trained service provider, 
especially physician (Miller & Wood, 2003; Rice, Hartmann-Boyce, & Stead, 2013; 
Sinclair, Bond, & Stead, 2004; Stead et al., 2013). This was because physician and 
other healthcare professionals could integrate the various aspects of an effective 
counselling to advise smokers to quit (Cornuz, 2007).  
Meanwhile, it is also noted that combination of different type of behavioural 
interventions would increase the cessation rate. Three or more self-help interventions 
would increase quit rates to 15% compared to no treatment of 8%. (Anderson & Wetter, 
1997). There is a small effect when individual counselling is more intensive 
counselling and added to pharmacotherapy (Niaura, 2008; Stead et al., 2013).  
Not only trained counsellor could support the smokers to quit smoking, the smokers’ 
family members and their peers are also play important roles. Environment (smoking 
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restriction, culture, advertising) of the quitters is undoubtedly affecting the ability of 
smokers to quit in some degree. Many ex-smokers have received some social support 
during their quitting journey. Social support is believed to provide high levels of 
emotional, informational, and instrumental support to the quitters (Westmaas, 
Bontemps-Jones, & Bauer, 2010). A meta-analysis concluded that enhancing partner 
support would improve smoking cessation quit rate at twelve or more months (Park, 
Schultz, Tudiver, Campbell, & Becker, 2002).  In another review by Westmaas et al. 
(2010), it was concluded that quit rates among socially supported quitters was not 
different from the control group (Westmaas et al., 2010). Despite these controversial 
findings, social support has been regarded as one of the main components in quitting 
smoking in smoking cessation guidelines (Disease Control Division, 2016; Foll, 
Melihan-Cheinin, Rostoker, Largue, & AFSSAPS, 1005; The Clinical Practice 
Guideline Treating Tobacco Use and Dependence 2008 Update Panel, 2008)  
Apart from giving education to the quitters, the quitters could also be further motivated 
by via competition and incentives, which was normally applied in workplace smoking 
cessation programs to encourage the smoking employees to participate or to quit at the 
predefined stage. A variety of incentives or rewards have been used, including cash 
payments, promotional items (such as T-shirt, pens, bags etc.), salary bonuses, lottery 
tickets, holidays and luxury goods (such as cars or boats). These rewards were paid for 
their attendance, were scaled relative to the quitters’ success or were guaranteed paid 
out irrespective of the outcome. Most of the rewards program are positive 
reinforcement but there are some programs implemented negative reinforcement 
where penalties will be imposed for non-compliance (Cahill & Perera, 2011). 
Competition is arranged where the participants were divided into groups to compete 
among the groups to encourage competitions to quit smoking among groups.  
